参考文献
1: Korb E, Herre M, Zucker-Scharff I, Gresack J, Allis CD, Darnell RB. Excess Translation of Epigenetic Regulators Contributes to Fragile X Syndrome and Is Alleviated by Brd4 Inhibition. Cell. 2017 Sep 7;170(6):1209-1223.e20. doi: 10.1016/j.cell.2017.07.033. Epub 2017 Aug 17. PubMed PMID: 28823556; PubMed Central PMCID: PMC5740873.
2: Dai X, Gan W, Li X, Wang S, Zhang W, Huang L, Liu S, Zhong Q, Guo J, Zhang J, Chen T, Shimizu K, Beca F, Blattner M, Vasudevan D, Buckley DL, Qi J, Buser L, Liu P, Inuzuka H, Beck AH, Wang L, Wild PJ, Garraway LA, Rubin MA, Barbieri CE, Wong KK, Muthuswamy SK, Huang J, Chen Y, Bradner JE, Wei W. Prostate cancer-associated SPOP mutations confer resistance to BET inhibitors through stabilization of BRD4. Nat Med. 2017 Sep;23(9):1063-1071. doi: 10.1038/nm.4378. Epub 2017 Aug 14. PubMed PMID: 28805820; PubMed Central PMCID: PMC5625299.
3: Nagaraja S, Vitanza NA, Woo PJ, Taylor KR, Liu F, Zhang L, Li M, Meng W, Ponnuswami A, Sun W, Ma J, Hulleman E, Swigut T, Wysocka J, Tang Y, Monje M. Transcriptional Dependencies in Diffuse Intrinsic Pontine Glioma. Cancer Cell. 2017 May 8;31(5):635-652.e6. doi: 10.1016/j.ccell.2017.03.011. Epub 2017 Apr 20. PubMed PMID: 28434841; PubMed Central PMCID: PMC5462626.
4: Nilsson LM, Green LC, Muralidharan SV, Demir D, Welin M, Bhadury J, Logan DT, Walse B, Nilsson JA. Cancer Differentiating Agent Hexamethylene Bisacetamide Inhibits BET Bromodomain Proteins. Cancer Res. 2016 Apr 15;76(8):2376-83. doi: 10.1158/0008-5472.CAN-15-2721. Epub 2016 Mar 3. PubMed PMID: 26941288.
5: Shahbazi J, Liu PY, Atmadibrata B, Bradner JE, Marshall GM, Lock RB, Liu T. The Bromodomain Inhibitor JQ1 and the Histone Deacetylase Inhibitor Panobinostat Synergistically Reduce N-Myc Expression and Induce Anticancer Effects. Clin Cancer Res. 2016 May 15;22(10):2534-44. doi: 10.1158/1078-0432.CCR-15-1666. Epub 2016 Jan 5. PubMed PMID: 26733615.
6: Gray LR, On H, Roberts E, Lu HK, Moso MA, Raison JA, Papaioannou C, Cheng WJ, Ellett AM, Jacobson JC, Purcell DF, Wesselingh SL, Gorry PR, Lewin SR, Churchill MJ. Toxicity and in vitro activity of HIV-1 latency-reversing agents in primary CNS cells. J Neurovirol. 2016 Aug;22(4):455-63. doi: 10.1007/s13365-015-0413-4. Epub 2016 Jan 4. PubMed PMID: 26727904.
7: Borbely G, Haldosen LA, Dahlman-Wright K, Zhao C. Induction of USP17 by combining BET and HDAC inhibitors in breast cancer cells. Oncotarget. 2015 Oct 20;6(32):33623-35. doi: 10.18632/oncotarget.5601. PubMed PMID: 26378038; PubMed Central PMCID: PMC4741790.
8: Gopalakrishnan R, Matta H, Tolani B, Triche T Jr, Chaudhary PM. Immunomodulatory drugs target IKZF1-IRF4-MYC axis in primary effusion lymphoma in a cereblon-dependent manner and display synergistic cytotoxicity with BRD4 inhibitors. Oncogene. 2016 Apr 7;35(14):1797-810. doi: 10.1038/onc.2015.245. Epub 2015 Jun 29. PubMed PMID: 26119939; PubMed Central PMCID: PMC4486341.
9: Lu J, Qian Y, Altieri M, Dong H, Wang J, Raina K, Hines J, Winkler JD, Crew AP, Coleman K, Crews CM. Hijacking the E3 Ubiquitin Ligase Cereblon to Efficiently Target BRD4. Chem Biol. 2015 Jun 18;22(6):755-63. doi: 10.1016/j.chembiol.2015.05.009. Epub 2015 Jun 4. PubMed PMID: 26051217; PubMed Central PMCID: PMC4475452.
10: Phthalimide-Conjugated Ligands Promote Selective Protein Destabilization. Cancer Discov. 2015 Jul;5(7):691. doi: 10.1158/2159-8290.CD-RW2015-104. Epub 2015 Jun 4. PubMed PMID: 26045013.
11: Laird GM, Bullen CK, Rosenbloom DI, Martin AR, Hill AL, Durand CM, Siliciano JD, Siliciano RF. Ex vivo analysis identifies effective HIV-1 latency-reversing drug combinations. J Clin Invest. 2015 May;125(5):1901-12. doi: 10.1172/JCI80142. Epub 2015 Mar 30. PubMed PMID: 25822022; PubMed Central PMCID: PMC4463209.
12: Bullen CK, Laird GM, Durand CM, Siliciano JD, Siliciano RF. New ex vivo approaches distinguish effective and ineffective single agents for reversing HIV-1 latency in vivo. Nat Med. 2014 Apr;20(4):425-9. doi: 10.1038/nm.3489. Epub 2014 Mar 23. PubMed PMID: 24658076; PubMed Central PMCID: PMC3981911.
13: Fiskus W, Sharma S, Qi J, Valenta JA, Schaub LJ, Shah B, Peth K, Portier BP, Rodriguez M, Devaraj SG, Zhan M, Sheng J, Iyer SP, Bradner JE, Bhalla KN. Highly active combination of BRD4 antagonist and histone deacetylase inhibitor against human acute myelogenous leukemia cells. Mol Cancer Ther. 2014 May;13(5):1142-54. doi: 10.1158/1535-7163.MCT-13-0770. Epub 2014 Jan 16. PubMed PMID: 24435446.
14: Bartholomeeusen K, Xiang Y, Fujinaga K, Peterlin BM. Bromodomain and extra-terminal (BET) bromodomain inhibition activate transcription via transient release of positive transcription elongation factor b (P-TEFb) from 7SK small nuclear ribonucleoprotein. J Biol Chem. 2012 Oct 19;287(43):36609-16. doi: 10.1074/jbc.M112.410746. Epub 2012 Sep 5. Erratum in: J Biol Chem. 2013 Apr 26;288(17):12214. PubMed PMID: 22952229; PubMed Central PMCID: PMC3476326.
15: Maxmen A. Cancer research: Open ambition. Nature. 2012 Aug 9;488(7410):148-50. doi: 10.1038/488148a. PubMed PMID: 22874946.
16: Oliver SS, Denu JM. Disrupting the reader of histone language. Angew Chem Int Ed Engl. 2011 Jun 20;50(26):5801-3. doi: 10.1002/anie.201101414. Epub 2011 May 25. PubMed PMID: 21618372; PubMed Central PMCID: PMC3327163.
